Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2023 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023

Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023 Projected cash runway guidance remains unchanged with funding...
April 18, 2023 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
March 16, 2023 08:00 ET | Source: Surface Oncology, Inc.

Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
March 09, 2023 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022

SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8...
February 28, 2023 16:15 ET | Source: Surface Oncology, Inc.

Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
February 02, 2023 08:00 ET | Source: Surface Oncology, Inc.

Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
January 05, 2023 07:30 ET | Source: Surface Oncology, Inc.

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical...
November 07, 2022 08:00 ET | Source: Surface Oncology, Inc.

Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
November 02, 2022 06:30 ET | Source: Surface Oncology, Inc.

Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort

– Two confirmed partial responses to SRF388 monotherapy treatment in squamous NSCLC; third patient with NSCLC experienced durable disease stabilization for over a year –– Company focusing...
October 19, 2022 07:00 ET | Source: Surface Oncology, Inc.

VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388

– Study reveals the structural basis of receptor activation and signaling by IL-27 cytokine –– Study elucidates how SRF388 binds to IL-27 to prevent interaction with the IL-27 receptor, inhibiting the...